Bevantolol

From Wikipedia, the free encyclopedia

Jump to: navigation, search
Bevantolol
Bevantolol.png
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
administration
Oral
ATC code C07AB06 (WHO)
Legal status
Legal status
  • unapproved, never marketed
Identifiers
Systematic (IUPAC) name: (RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyl]amine
CAS Number 59170-23-9 YesY
PubChem (CID) 2372
DrugBank DB01295 YesY
ChemSpider 2282 YesY
UNII 34ZXW6ZV21 YesY
ChEBI CHEBI:238698 YesY
ChEMBL CHEMBL314010 YesY
Chemical and physical data
Formula C20H27NO4
Molar mass 345.43 g/mol
3D model (Jmol) Interactive image
Chirality Racemic mixture
  (verify)

Bevantolol (INN) was a drug candidate for angina and hypertension that acted as both a beta blocker and a calcium channel blocker.[1][2] It was discovered and developed by Warner-Lambert[3] but in January 1989 the company announced that it had withdrawn the New Drug Application; the company's chairman said: "Who needs the 30th beta blocker?"[4] As of 2016 it wasn't marketed in the US, UK, or Europe and the authors of a Cochrane review could find no product monograph for it.[5]

References[edit]

  1. ^ Frishman, WH; Goldberg, RJ; Benfield, P (January 1988). "Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.". Drugs. 35 (1): 1–21. PMID 2894292. 
  2. ^ Vaughan Williams, EM (July 1987). "Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions.". Journal of clinical pharmacology. 27 (7): 450–60. PMID 2888789. 
  3. ^ McPherson, Edwin M. (2007). Pharmaceutical Manufacturing Encyclopedia. (3rd ed. ed.). Burlington: Elsevier. pp. 618–619. ISBN 9780815518563. 
  4. ^ "Warner-Lambert Pipeline Narrowed to 40 Active Research Compounds". Pink Sheet. 30 January 1989. 
  5. ^ Wong, GW; Boyda, HN; Wright, JM (10 March 2016). "Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertension.". The Cochrane database of systematic reviews. 3: CD007451. PMID 26961574.